Grandfield & Dodd LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 5.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,046 shares of the medical research company’s stock after selling 3,885 shares during the period. Grandfield & Dodd LLC’s holdings in Amgen were worth $10,684,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Oakworth Capital Inc. increased its stake in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares in the last quarter. Valley National Advisers Inc. increased its stake in Amgen by 4.8% in the second quarter. Valley National Advisers Inc. now owns 714 shares of the medical research company’s stock valued at $109,000 after buying an additional 33 shares in the last quarter. Glassman Wealth Services increased its stake in Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock valued at $110,000 after buying an additional 600 shares in the last quarter. Integrated Wealth Management increased its stake in Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock valued at $141,000 after buying an additional 3 shares in the last quarter. Finally, Delta Asset Management LLC TN increased its stake in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock valued at $155,000 after buying an additional 85 shares in the last quarter. Institutional investors and hedge funds own 77.90% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded down 0.23% on Wednesday, hitting $158.40. 447,918 shares of the stock were exchanged. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $176.85. The company has a 50-day moving average of $146.78 and a 200-day moving average of $159.07. The stock has a market cap of $117.84 billion, a price-to-earnings ratio of 15.86 and a beta of 1.14.
Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.79 by $0.23. Amgen had a net margin of 33.63% and a return on equity of 29.27%. The business earned $5.81 billion during the quarter, compared to analysts’ expectations of $5.73 billion. During the same period in the previous year, the company earned $2.72 earnings per share. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. On average, equities analysts predict that Amgen Inc. will post $11.55 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 8th. Investors of record on Wednesday, February 15th will be given a dividend of $1.15 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.00. The ex-dividend date is Monday, February 13th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.90%. Amgen’s dividend payout ratio is currently 39.92%.
WARNING: This piece of content was reported by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/grandfield-dodd-llc-sells-3885-shares-of-amgen-inc-amgn/344520.html.
Several research firms have issued reports on AMGN. Credit Suisse Group set a $206.00 price target on Amgen and gave the company a “buy” rating in a research note on Saturday, September 17th. Leerink Swann reissued a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. RBC Capital Markets set a $190.00 price target on Amgen and gave the company a “buy” rating in a research note on Sunday, October 30th. Chardan Capital raised Amgen from a “sell” rating to a “neutral” rating in a research report on Tuesday, December 13th. Finally, Vetr downgraded Amgen from a “strong-buy” rating to a “buy” rating and set a $167.77 target price on the stock. in a research report on Thursday, November 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Amgen currently has an average rating of “Hold” and an average target price of $179.48.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.